Follow Veeva Systems to never miss an important update.
Wells Fargo kept its overweight rating, a sign they expect the stock to perform better than the broader market. Their new $400 price target is about 30 percent higher than where the stock trades today and sits well above the average analyst target of $307.
This confidence comes as the company moves its customers from Salesforce technology onto its own platform, Vault CRM. If successful, this shift should help the business keep more of every dollar it earns by removing the need to pay licensing fees to an outside partner.
Source: Wells Fargo
BTIG set a new price target of $360 for the software maker on Monday. This is notably higher than the average analyst target, which currently sits at $303, right where the stock is trading today. Veeva is in the middle of moving its customers from Salesforce technology to its own platform to save on licensing costs. This higher target suggests confidence that the shift is progressing well and will lead to higher profit margins over time.
Source: BTIG
UCB has signed on to use Veeva's new Vault CRM, a platform designed to help drug companies manage their sales and customer relationships. This is a key win for Veeva as it works to move its entire customer base off of Salesforce's technology and onto its own in-house system.
By moving customers to its own platform, Veeva can stop paying licensing fees to Salesforce, which should leave the company with more profit from every dollar it earns. This deal shows that large, global drugmakers are willing to make the switch, supporting the idea that Veeva can successfully transition its customers without losing them to rivals.
Source: PRNewsWire
At its recent summit, Veeva showcased its new AI tools alongside several of the world's largest pharmaceutical companies. Leaders from firms like AstraZeneca, Roche, and Novo Nordisk are adopting these innovations to automate complex tasks for their sales teams and better manage their data.
This is a key step in Veeva's plan to move customers onto its own proprietary platform. By proving that industry giants are willing to use its new AI features, Veeva is showing it can deepen its grip on the life sciences market while reducing its reliance on outside technology partners. This shift is vital for the company to grow its profit margins over the long term.
Source: PRNewsWire
Barclays raised its price target for Veeva to $360, up from $315. This move puts the firm's target well above the average analyst estimate of $294. While the stock has risen recently, this change suggests analysts are becoming more confident in the company's ability to grow as it moves customers onto its own software platform.
Source: Barclays
Management consistently sets a bar they can clear, delivering eight straight quarters of steady growth and reliable beats that prove they have a tight grip on their complex business.
| Expectation | |
|---|---|
| EPS | $2.34 |
| Revenue | $935M |
Follow Veeva Systems to get the latest and most important updates.
Follow VEEV